In type 2 diabetes, use of metformin [97, 98], dipeptidyl peptidase-4 (DPP-4) inhibitors [99] and glucagon-like peptide-1 receptor agonists (GLP1-RAs) [100] appears to be neutral/beneficial with regard to BMD and fracture risk. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.